Caffeine consumption and risk of dyskinesia in CALM‐PD

Abstract

Background Adenosine A2A receptor antagonists reduce or prevent the development of dyskinesia in animal models of levodopa-induced dyskinesia. Methods We examined the association between self-reported intake of the A2A receptor antagonist caffeine and time to dyskinesia in the Comparison of the Agonist Pramipexole with Levodopa on Motor Complications of Parkinson’s Disease (CALM-PD) and CALM Cohort extension studies, using a Cox proportional hazards model adjusting for age, baseline Parkinson’s severity, site, and initial treatment with pramipexole or levodopa. Results For subjects who consumed > 12 ounces of coffee/day, the adjusted hazard ratio for the development of dyskinesia was 0.61 (95% confidence interval, 0.37–1.01) compared to subjects who consumed < 4 ounces/day. For subjects who consumed between 4 and 12 ounces/day, the adjusted hazard ratio was 0.73 (C.I. 0.46–1.15) (test for trend, p = 0.05). Conclusions These results support the possibility that caffeine may reduce the likelihood of developing dyskinesia.

Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications

“…To examine the association between baseline PET data and time to onset of wearing-off, LID, and any motor complication (wearing-off/dyskinesia), we used a Cox proportional hazards model, which was adjusted for relevant covariates. Similar to previous studies, 6,21,22 sex, age at symptom onset, disease duration at baseline, baseline UPDRS ADL and motor scores, baseline weight, treatment allocation (initial randomization to cabergoline/levodopa), and antiparkinsonian therapy at time of motor complication onset (antiparkinsonian agents, levodopa LED) were entered as covariates into this model. A stepwise selection process, with significance levels for both entry and retention in the model set at 0.05, was used to select the most significant predictors.…”

Inverse association between yerba mate consumption and idiopathic Parkinson's disease. A case–control study

“…Nevertheless, the adenosine A2A receptor antagonism attributed to YM caffeine could be the best explanation for the protective role of YM in the risk of PD [9,37,38]. An extensive review of the literature supports the potential neuroprotective and pharmacological effects of caffeine mediated by A2A receptor antagonism.…”

Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice

“…Caffeine has attracted considerable attention in the management of nonmotor symptoms of PD that do not improve with the current DAergic drugs (Prediger, 2010). Accordingly, in a 6-week randomized placebo-controlled clinical trial, caffeine per se improved motor functions in PD patients (Postuma et al, 2012) and was also reported to reduce the risk of dyskinesia in PD patients receiving DAergic agents (Wills et al, 2013).…”